Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.
Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity
Almost a year ago, Sanofi made history for the wrong reasons. Last October, CEO Paul Hudson announced strategic changes including boosting R&D spending and pulling